pf-06447475 has been researched along with Leukemia--Myeloid--Acute* in 1 studies
1 other study(ies) available for pf-06447475 and Leukemia--Myeloid--Acute
| Article | Year |
|---|---|
Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia.
Serine/threonine-protein kinases 3 and 4 (STK3 and STK4, respectively) are key components of the Hippo signaling pathway, which regulates cell proliferation and death and provides a potential therapeutic target for acute myeloid leukemia (AML). Herein, we report the structure-based design of a series of pyrrolopyrimidine derivatives as STK3 and STK4 inhibitors. In an initial screen, the compounds exhibited low nanomolar potency against both STK3 and STK4. Crystallization of compound Topics: Animals; Female; Hippo Signaling Pathway; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Serine-Threonine Kinase 3 | 2022 |